<DOC>
	<DOCNO>NCT01105364</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , contrast-enhanced ultrasound , may help measure patient 's response treatment drug sunitinib malate , sorafenib tosylate , bevacizumab , allow doctor plan good treatment . PURPOSE : This clinical trial study ultrasonography assess antiangiogenic treatment patient advance kidney cancer .</brief_summary>
	<brief_title>Ultrasound Assessing Antiangiogenic Treatment Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine contrast-enhanced ultrasonography ( CEUS ) study target metastasis renal cancer lead early assessment pharmacodynamic effect antiangiogenic treatment patient advance renal cancer . Secondary - To determine association functional change microvascularization target lesion CEUS early objective response lesion indicate time progression . - To determine association functional change microvascularization target lesion CEUS early objective response lesion indicate global survey . - To determine tolerance antiangiogenic treatment patient . - To determine relationship functional change microvascularization target lesion objective response lesion ( RECIST criterion ) case metastasis target lesion . OUTLINE : Patients undergo contrast-enhanced ultrasonography ( CEUS ) stabilize sulphur hexafluoride microbubble-based contrast agent injection . CEUS do within 8 day prior , 30 day first administration , 3 month receive antiangiogenesis treatment ( e.g. , sunitinib malate , sorafenib tosylate , bevacizumab ) . Patients also undergo compute tomography magnetic resonance image evaluate tumoral target . After completion study treatment , patient follow 2 year .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis advance renal cancer Planning receive antiangiogenic treatment Detection target hepatic metastasis visible , locate , sized conventional sonography CT scan and/or MRI PATIENT CHARACTERISTICS : No active cardiac disease No severe arterial hypertension PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>